之江生物
(688317)
| 流通市值：34.03亿 | | | 总市值：34.03亿 |
| 流通股本：1.92亿 | | | 总股本：1.92亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,642,785,204.33 | 2,783,392,638.52 | 2,744,475,186.36 | 2,765,562,458.72 |
| 应收票据及应收账款 | 50,137,606.51 | 55,266,044.02 | 76,228,303.43 | 84,148,790.28 |
| 其中：应收票据 | 2,218,598.82 | 247,022 | 879,546 | 539,827 |
| 应收账款 | 47,919,007.69 | 55,019,022.02 | 75,348,757.43 | 83,608,963.28 |
| 预付款项 | 10,357,982.22 | 11,838,697.34 | 12,788,745.39 | 12,494,571.66 |
| 其他应收款合计 | 5,082,368.97 | 4,635,986.13 | 6,901,504.14 | 6,849,450.05 |
| 存货 | 50,647,478.79 | 57,369,192.76 | 213,761,093.04 | 227,996,109.08 |
| 其他流动资产 | 23,656,750.16 | 23,103,214.83 | 18,123,637.24 | 22,100,327.65 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,931,380,855.1 | 2,935,605,773.6 | 3,072,278,469.6 | 3,119,151,707.44 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 95,405,975.75 | 95,461,701.3 | 97,497,105.22 | 97,688,306.39 |
| 投资性房地产 | - | 0 | - | 0 |
| 固定资产 | 664,189,253.89 | 675,576,117.73 | 704,264,631.87 | 717,897,483.63 |
| 在建工程 | 1,226,580.42 | 343,000 | 42,600 | 1,296,310 |
| 使用权资产 | 4,536,252.46 | 5,028,587.15 | 5,013,958.25 | 5,519,763.45 |
| 无形资产 | 7,258,725.83 | 7,800,921.75 | 5,394,713.01 | 5,616,515.49 |
| 商誉 | 5,404,994.34 | 5,404,994.34 | 5,404,994.34 | 5,404,994.34 |
| 长期待摊费用 | 3,648,943.97 | 3,824,633.06 | 3,968,822.15 | 2,549,677.9 |
| 递延所得税资产 | 60,208,576.17 | 60,797,766.19 | 40,183,918.06 | 38,931,486.56 |
| 其他非流动资产 | 265,000 | 106,596 | 2,431,051.32 | 2,431,051.32 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 842,144,302.83 | 854,344,317.52 | 864,201,794.22 | 877,335,589.08 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,773,525,157.93 | 3,789,950,091.12 | 3,936,480,263.82 | 3,996,487,296.52 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 74,140,312.17 | 78,752,406.72 | 78,107,635.31 | 87,234,440.81 |
| 应付账款 | 74,140,312.17 | 78,752,406.72 | 78,107,635.31 | 87,234,440.81 |
| 合同负债 | 12,166,719.22 | 15,280,381.97 | 13,419,119.45 | 17,097,571.81 |
| 应付职工薪酬 | 37,947,350.89 | 40,929,438.43 | 51,975,759.14 | 51,620,125.63 |
| 应交税费 | 3,087,033.49 | 3,023,577.08 | 3,202,379.82 | 2,895,392.01 |
| 其他应付款合计 | 6,321,547.67 | 5,791,518.97 | 5,846,561.96 | 6,569,430.92 |
| 一年内到期的非流动负债 | 1,680,955.69 | 1,732,454.28 | 1,464,821.36 | 1,597,812.59 |
| 其他流动负债 | 1,572,026.81 | 478,810.09 | 462,527.75 | 666,445.86 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 136,915,945.94 | 145,988,587.54 | 154,478,804.79 | 167,681,219.63 |
| 非流动负债: | | | | |
| 长期借款 | 99,000,000 | - | - | - |
| 租赁负债 | 3,090,321.31 | 3,193,894.52 | 3,880,552.35 | 3,837,407.42 |
| 递延收益 | 2,712,350.44 | 3,880,846.55 | 4,716,698.41 | 5,640,912.23 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 104,802,671.75 | 7,074,741.07 | 8,597,250.76 | 9,478,319.65 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 241,718,617.69 | 153,063,328.61 | 163,076,055.55 | 177,159,539.28 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 192,157,999 | 192,157,999 | 192,157,999 | 194,704,350 |
| 资本公积 | 2,050,702,003.19 | 2,050,702,003.19 | 2,050,702,003.19 | 2,150,189,569.46 |
| 减:库存股 | 124,380,266.25 | 35,331,332.71 | 35,331,332.71 | 130,798,591.72 |
| 其他综合收益 | -8,896,694.19 | -8,882,738.46 | -7,700,635.79 | -7,358,296.53 |
| 盈余公积 | 97,352,175 | 97,352,175 | 97,352,175 | 97,352,175 |
| 未分配利润 | 1,324,871,323.49 | 1,340,888,656.49 | 1,476,223,999.58 | 1,515,238,551.03 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,531,806,540.24 | 3,636,886,762.51 | 3,773,404,208.27 | 3,819,327,757.24 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,531,806,540.24 | 3,636,886,762.51 | 3,773,404,208.27 | 3,819,327,757.24 |
| 负债和股东权益合计 | 3,773,525,157.93 | 3,789,950,091.12 | 3,936,480,263.82 | 3,996,487,296.52 |
| 公告日期 | 2025-04-30 | 2025-04-25 | 2024-10-30 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |